In the multivariate analysis, after the adjustment for ECOG PS, smoking status, tumor grade, clinical stage, EGFR status and type of response to first-line therapy, the LKB1-positive expression remained a significant factor for PFS (HR 0.20 (0.11–0.38)). The gene discussed is EGFR; the disease is neoplasm.